Canaccord raised the firm’s price target on Hinge Health (HNGE) to $65 from $61 and keeps a Buy rating on the shares. The firm said they posted another stellar quarter where the outlook appears favorable both in the near-term with a guidance raise that more than factors in the 3Q beat and longer-term with discussion of the potential of the new HingeSelect offering and foreshadowing of a service line expansion that may be sooner than previously anticipated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
- Hinge Health price target raised to $65 from $62 at Barclays
- Hinge Health Reports Strong Q3 2025 Financial Results
- Hinge Health: Strong Financial Performance and Growth Potential Amidst Rising Demand for Digital MSK Solutions
- Hinge Health reports Q3 EPS (2c) vs 1c last year
- Hinge Health sees Q4 revenue $155M-$157M, consensus $145.42M